The HIV-1 non-nucleoside reverse transcriptase inhibitors (Part V *): Capravirine and its analogues

Current Medicinal Chemistry

Volumn 19, Issue 36, 2012, Pages 6138-6149

  Li, X ^a   Zhan, P ^a   De Clercq, E ^b   Liu, X ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AIDS; Analogue based strategies; Binding mode; Capravirine; HIV; NNRTIs; Reverse transcriptase (RT)

Indexed keywords

1 (2 AMINO 6 METHYL 5 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 BENZYLSULFONAMIDO 6 METHYL 2 PYRIDINONE; CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; LERSIVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRODRUG; RILPIVIRINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CHEMICAL MODIFICATION; CLINICAL EVALUATION; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDIZATION; LIGAND BINDING; MEDICAL LITERATURE; MOLECULAR EVOLUTION; NONHUMAN; PHARMACOPHORE; PROCESS OPTIMIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; IMIDAZOLES; MOLECULAR DOCKING SIMULATION; NUCLEOSIDES; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; SULFUR COMPOUNDS;

EID: 84871276614     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804485764     Document Type: Review

References (87)

1. Hirschel, B.; Francioli, P. Progress and problems in the fight against AIDS. N. Engl. J. Med., 1998, 338, 906-908.
2. Hui, Xu. Progress of Bis (heteroaryl) piperazines (BHAPs) as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) against Human Immunodeficiency Virus Type 1 (HIV-1). Mini. Rev. Med. Chem., 2010, 10, 62-72.
3. Sluis-Cremer, N.; Tachedjian, G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res., 2008, 134, 147-156.
4. Alcaro, S.; Artese, A.; Ceccherini-Silberstein, F.; Chiarella, V.; Dimonte, S.; Ortuso, F.; Perno, C. F. Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. Curr. Med. Chem., 2010, 17, 290-308.
5. http://www.fda.gov/Drugs/default.htm
6. Ilina, T.; Parniak, M. A. Inhibitors of HIV-1 reverse transcriptase. Adv. Pharmacol., 2008, 56, 121-167.
7. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res., 2008, 134, 171-185.
8. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov., 2007, 6, 1001-1018.
9. Sax, P. E. FDA approval: etravirine. AIDS. Clin. Care, 2008, 20, 17-18.
10. Intelence (etravirine) - Important Drug Warning. 2009, Tibotec Therapeutics. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsfor HumanMedicalProducts/ucm180579.htm.
11. Ford, N.; Lee, J.; Andrieux-Meyer, I.; Calmy, A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resourcelimited settings. HIV. AIDS., 2011, 3, 35-44.
12. (a) Zhan, P.; Li, Z.; Liu, X.; De Clercq, E. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini. Rev. Med. Chem., 2009, 9, 1014-1023.
13. (b) Chen, X.; Zhan, P.; Li, D.; De Clercq, E.; Liu, X. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs. Curr. Med. Chem., 2011, 18, 359-376.
14. (c) Chen, W. M.; Zhan, P.; Wu, J. D.; Li, Z. Y.; Liu, X. Y. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. Curr. Pharm. Des., 2012, 18, 4165-4186.
15. (d) Tian, Y.; Zhan, P.; Rai, D.; Zhang, J.; De Clercq, E.; Liu, X. Recent advances in the research of 2, 3-diaryl-1, 3-thiazolidin-4-one derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr. Med. Chem., 2012, 19, 2026-2037.
16. Zhao, H.; Guo, Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov. Today, 2009, 14, 516-522.
17. DiMasi, J. A.; Faden, L. B. Competitiveness in follow-on drug R&D: a race or imitation? Nat. Rev. Drug. Discov., 2011, 10, 23-27.
18. Fischer, J.; Ganellin, C. R. Analogue-based Drug Discovery, Wiley-VCH Verlag GmbH, Weinheim, p. XXIII.
19. (a) Zhan, P.; Liu, X.; Fang, Z.; Li, Z.; Pannecouque, C.; De Clercq, E. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1, 2, 3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem., 2009, 44, 4648-4653.
20. (b) Zhan, P.; Liu, X.; Fang, Z., Pannecouque, C.; De Clercq, E. 1, 2, 3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorg. Med. Chem., 2009, 17, 6374-6379.
21. (c) Zhan, P.; Liu, X.; Li, Z.; Fang, Z.; Li, Z.; Wang, D.; Pannecouque, C.; De Clercq, E. Novel 1, 2, 3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorg. Med. Chem., 2009, 17, 5920-5927.
22. (d) Zhan, P.; Liu, X.; Zhu, J.; Fang, Z.; Li, Z.; Pannecouque, C.; De Clercq, E. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem., 2009, 17, 5775-5781.
23. (e) Zhan, P.; Liu, X.; Cao, Y.; Wang, Y.; Pannecouque, C.; De Clercq, E. 1, 2, 3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 5368-5371.
24. (e) Zhan, P.; Liu, X.; Li, Z.; Fang, Z.; Pannecouque, C.; De Clercq, E. 1, 2, 3-thiadiazole thioacetanilides. Part 2: Synthesis and biological evaluation of a new series of 2-{[4-(3, 4-dichlorophenyl)-1, 2, 3-thiadiazol-5-yl]sulfanyl} acetanilides as HIV-1 inhibitors. Chem. Biodivers., 2010, 7, 1717-1727.
25. (f) Zhan, P.; Liu, H.; Liu, X.; Wang, Y.; Pannecouque, C.; Witvrouw, M.; De Clercq, E. Synthesis and anti-HIV activity evaluation of novel N'-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio] acetohy drazides. Med. Chem. Res., 2009, 19, 652-663.
26. (g) Zhan, P.; Chen, X.; Li, X.; Li, D.; Tian, Y.; Chen, W.; Pannecouque, C.; De Clercq, E.; Liu, X. Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2, 4-Dichlorophenyl)-2H-1, 2, 4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. Eur. J. Med. Chem., 2011, 46, 5039-5045.
27. (h) Zhan, P.; Wang, L.; Liu, H.; Chen, X.; Li, X.; Jiang, X.; Zhang, Q.; Liu, X.; Pannecouque, C.; Naesens, L.; De Clercq, E.; Liu A.; Du, G. Arylazolyl (azinyl) thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch. Pharm. Res., 2012, 35, 1037-1048.
28. Watson, K.; Krippner, G.; Stanislawski, P.; McConnell, D. Heterocyclic compounds as antiviral agents. EP2314582 A1, 2011.
29. Zhan, P.; Li, D.; Chen, X.; Liu, X.; De Clercq, E. Functional roles of azoles motif in anti-HIV agents. Curr. Med. Chem., 2011, 18, 29-46.
30. Fujiwara, T.; Sato, A.; El-Farrash, M.; Miki, S.; Abe, K.; Isaka, Y.; Kodama, M.; Wu, Y.; Chen, L. B.; Harada, H.; Sugimoto, H.; Hatanaka, M.; Hinuma, Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 1998, 42, 1340-1345.
31. Sato, A.; Hammond, J.; Alexander, T. N.; Graham, J. P.; Binford, S.; Sugita, K.; Sugimoto, H.; Fujiwara, T.; Patick, A. K. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res., 2006, 70, 66-74.
32. Mowbray, C. E.; Burt, C.; Corbau, R.; Perros, M.; Tran, I.; Stupple, P. A.; Webster, R.; Wood, A. Pyrazole NNRTIs 1: design and initial optimisation of a novel template. Bioorg. Med. Chem. Lett., 2009, 19, 5599-5602.
33. Zhan, P.; Liu, X.; Li, Z.; Pannecouque, C.; De Clercq, E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 2009, 16, 3903-3917.
34. Bu, H. Z.; Pool, W. F.; Wu, E. Y.; Raber, S. R.; Amantea, M. A.; Shetty, B. V. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab. Dispos., 2004, 32, 689-698.
35. Ren, J.; Nichols, C.; Bird, L. E.; Fujiwara, T.; Sugimoto, H.; Stuart, D. I.; Stammers, D. K. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J. Biol. Chem., 2000, 275, 14316-14320.
36. (a) Pelemans, H.; Esnouf, R.; De Clercq, E.; Balzarini, J. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol. Pharmacol., 2000, 57, 954-960.
37. (b) Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. Med. Chem., 2005, 48, 7153-7165.
38. (c) Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S. S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Di Mattia, M.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations. J. Med. Chem., 2009, 52, 1224-1228.
39. Gewurz, B. E.; Jacobs, M.; Proper, J. A.; Dahl, T. A.; Fujiwara, T.; Dezube, B. J. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis., 2004, 190, 1957-1961.
40. (a) Jones, L. H.; Newman, S. D.; Swain, N. A. Preparation of 3-chloro-5-cyano thiophenyl substituted imidazole derivatives as HIV-1 reverse transcriptase inhibitors and modulators. WO2006072833 A1, 2006.
41. (b) Jones, L. H.; Mohammed, S.; Mowbray, C. E. Newman, S. D.; Selby, M. D.; Stupple, P. A.; Swain, N. A. Sulfur-linked imidazole compounds for the treatment of HIV. WO2005100322 A1, 2005.
42. (c) Jones, L. H.; Newman, S. D. Imidazole derivatives as enzyme reverse transcriptase modulators. US2008176919 A1, 2008.
43. (a) Sugimoto, H.; Fujiwara, T. Preparation of benzyl-and phenylthioimidazole derivatives as specific inhibitors of HIV-1 reverse transcriptase. WO9610019 A1, 1996.
44. (b) Sugimoto, H.; Fujiwara, T. Imidazole derivative. EP0786455 A1, 1997.
45. Sugimoto, H.; Ogata, M.; Matsumoto, H.; Sugita, K.; Sato, A.; Fujiwara, T. Imidazole derivatives having anti-HIV activity. EP 552060 A1, 1993.
46. Dymock, B. W.; Jones P. Midazolone Derivatives For the Treatment of Viral Diseases. WO0242279 A1, 2002.
47. De Clercq, E.; Van Aerschot, A.; Herdewijn, P.; Lagoja, I.; Pannecoucque, Christophe. Preparation and use of N-aminoimidazole derivatives as HIV inhibitors. WO02068395 A1, 2002.
48. Dymock, B. W.; Jones, P. S.; Merrett, J. H.; Parratt, M. J. Pyrazole Derivatives for the Treatment of Viral Diseases. WO0230907 A1, 2001.
49. Jones, L. H.; Mowbray, C. E.; Price, D. A.; Selby, M. D.; Stupple, P. A. Pyrazole Derivatives for Treating HIV. WO02085860 A1, 2002.
50. Jones, L. H.; Mowbray, C. E.; Price, D. A. Pyrazole derivatives. US2005004129 A1, 2005.
51. Price, D. A.; Selby, M. D.; Stupple, P. A. Pyrazole Derivatives. WO2004031178 A1, 2004.
52. Corbau, R. G.; Mowbray, C. E.; Perros, M.; Stupple, P. A.; Wood, A. Pyrazole Derivatives. WO0204424 A1, 2001.
53. Dymock, B.; Jones, P.; Merrett, J.; Parkes, K.; Parrratt, M. Pyrrole Derivatives for Treating AIDS. WO0202524 A1, 2002.
54. Olson, M.; Di, G. M. Preparation of triazole derivatives for treating HIV infections. US2005209287 A1, 2005.
55. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem., 2005, 12, 23-49.
56. Loksha, Y. M.; El-Barbary, A. A.; El-Badawi, M. A.; Nielsen, C.; Pedersen, E. B. Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues. Bioorg. Med. Chem., 2005, 13, 4209-4220.
57. Mowbray, C. E.; Burt, C.; Corbau, R.; Gayton, S.; Hawes, M.; Perros, M.; Tran, I.; Price, D. A.; Quinton, F. J.; Selby, M. D.; Stupple, P. A.; Webster, R.; Wood, A. Pyrazole NNRTIs 4: selection of UK-453, 061 (lersivirine) as a development candidate. Bioorg. Med. Chem. Lett., 2009, 19, 5857-5860.
58. (a) Mowbray, C. E.; Corbau, R.; Hawes, M.; Jones, L. H.; Mills, J. E.; Perros, M.; Selby, M. D.; Stupple, P. A.; Webster, R.; Wood, A. Pyrazole NNRTIs 3: optimisation of physicochemical properties. Bioorg. Med. Chem. Lett., 2009, 19, 5603-5606.
59. (b) Fätkenheuer, G.; Staszewski, S.; Plettenburg, A.; Hackman, F.; Layton, G.; McFadyen, L.; Davis, J.; Jenkins, T. M. Activity, pharmacokinetics and safety of lersivirine (UK-453, 061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS., 2009, 23, 2115-2122.
60. (c) Corbau, R.; Mori, J.; Phillips, C.; Fishburn, L.; Martin, A.; Mowbray, C.; Panton, W.; Smith-Burchnell, C.; Thornberry, A.; Ringrose, H.; Knöchel, T.; Irving, S.; Westby, M.; Wood, A.; Perros, M. Lersivirine: a Non-Nucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus-1. Antimicrob. Agents Chemother., 2010, 54, 4451-4463.
61. (a) Di Santo, R.; Costi, R.; Artico, M.; Miele, G.; Lavecchia, A.; Novellino, E.; Bergamini, A.; Cancio, R.; Maga, G. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptaseinhibitors: Synthesis, structureactivity relationships, and docking studies (part 1). Chem. Med. Chem., 2006, 1, 1367-1378.
62. (b) Lavecchia, A.; Costi, R.; Artico, M.; Miele, G.; Novellino, E.; Bergamini, A.; Crespan, E.; Maga, G.; Di Santo, R. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1reverse transcriptase inhibitors: Synthesis, structure-activity relationships, and docking studies (part 2). Chem. Med. Chem., 2006, 1, 1379-1390
63. Kirschberg, T. A.; Balakrishnan, M.; Huang, W.; Hluhanich, R.; Kutty, N.; Liclican, A. C.; McColl, D. J.; Squires, N. H.; Lansdon, E. B. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase- structure activity relationships and crystallographic analysis. Bioorg. Med. Chem. Lett., 2008, 18, 1131-1134.
64. Viegas-Junior, C.; Danuello, A.; Da Silva Bolzani, V.; Barreiro, E. J.; Fraga, C. A. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem., 2007, 14, 1829-1852.
65. Terasaka, T.; Kinoshita, T.; Kuno, M.; Nakanishi, I. A highly potent nonnucleoside adenosine deaminase inhibitor: Efficient drug discovery by intentional lead hybridization. J. Am. Chem. Soc., 2004, 126, 34-35.
66. Rotili, D.; Tarantino, D.; Artico, M.; Nawrozkij, M. B.; Gonzalez-Ortega, E.; Clotet, B.; Samuele, A.; Este, J. A.; Maga, G.; Mai, A. Diarylpyrimidinedihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. J. Med. Chem., 2011, 54, 3091-3096.
67. Jones, L. H.; Allan, G.; Barba, O.; Burt, C.; Corbau, R.; Dupont, T.; Knöchel, T.; Irving, S.; Middleton, D. S.; Mowbray, C. E.; Perros, M.; Ringrose, H.; Swain, N. A.; Webster, R.; Westby, M.; Phillips, C. Novel indazole nonnucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J. Med. Chem., 2009, 52, 1219-1223.
68. Deng, B. L.; Hartman, T. L.; Buckheit, R. W.; Jr Pannecouque, C.; De Clercq, E.; Fanwick, P. E.; Cushman, M. Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Med. Chem., 2005, 48, 6140-6155.
69. Deng B. L.; Hartman, T. L.; Buckheit, R. W.; Jr Pannecouque, C.; De Clercq, E.; Cushman, M. Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of nonnucleosidereverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents. J. Med. Chem., 2006, 49, 5316-5323.
70. Jones, L. H.; Allan, G.; Corbau, R.; Hay, D.; Middleton, D. S.; Mowbray, C. E.; Newman, S. D.; Perros, M.; Randall, A.; Vuong, H.; Webster, R.; Westby, M.; Williams, D. Optimization of 5-aryloxyimidazole nonnucleoside reverse transcriptase inhibitors. Chem. Med. Chem., 2008, 3, 1756-1762.
71. Silva, A. T.; Chung, M. C.; Castro, L. F.; Güido, R. V.; Ferreira, E. I. Advances in prodrug design. Mini. Rev. Med. Chem., 2005, 5, 893-914.
72. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketedand investigational prodrugs. J. Med. Chem., 2004, 47, 2393-2404.
73. Chen, J. M.; Chen, X.; Kim, C. U.; Lee, W. A.; Tario, J. D.; Xu, L.; Nelson, P. H. Non-nucleoside reverse transcriptase inhibitors. WO 03091264 A1, 2003.
74. Raju, T. N. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905-98). Lancet, 2000, 355, 1022.
75. Zhan, P.; Chen, X.; Li, D.; Fang, Z.; De Clercq, E.; Liu, X. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Med. Res. Rev., 2011, doi: 10.1002/med.20241.
76. Patel, Y.; Gillet, V. J.; Bravi, G.; Leach, A. R. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comput. Aided. Mol. Des., 2002, 16, 653-681.
77. Iwase, K.; Hirono, S. Estimation of active conformations of drugs by a new molecular superposing procedure. J. Comput. Aided Mol. Des., 1999, 13, 499-512.
78. (a) Daeyaert, F.; Walczak, B.; Xu, Q. S.; Daeyaert, F.; De Jonge, M. R.; Heeres, J.; Koymans, L. M.; Lewi, P. J.; Vinkers, H. M.; Janssen, P. A. Massart, D. L. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Proteins, 2004, 54, 526-533
79. (b) Daeyaert, F.; Walczak, B.; Xu, Q. S.; Daeyaert, F.; De Jonge, M. R.; Heeres, J.; Koymans, L. M.; Lewi, P. J.; Vinkers, H. M.; Janssen, P. A. Massart, D. L. Classification and regression trees-studies of HIV reverse transcriptase inhibitors. J. Chem. Inf. Comput. Sci., 2004, 44, 716-726.
80. Sluis-Cremer, N.; Temiz, N. A.; Bahar, I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV. Res., 2004, 2, 323-32.
81. Esnouf, R. M.; Ren, J.; Hopkins, A. L.; Ross, C. K.; Jones, E. Y.; Stammers, D. K.; Stuart, D. I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis (heteroaryl) piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA., 1997, 94, 3984-3989.
82. Duarte, CD.; Barreiro, E. J.; Fraga, C. A. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini. Rev. Med. Chem., 2007, 7, 1108-1119.
83. Zhao, H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov. Today, 2007, 12, 149-155.
84. Mitchell, M. L.; Son, J. C.; Lee, I. Y.; Lee, C. K.; Kim, H. S.; Wang, J.; Hayes, J.; Wang, M.; Paul, A.; Lansdon, E. B.; Chen, J. M.; Eisenberg, G.; Geleziunas, R.; Xu, L.; Kim, C. U. N1-Heterocyclic pyrimidinediones as nonnucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett, 2010, 20, 1585-1588.
85. (a) Kertesz, D. J.; Brotherton-Pleiss, C.; Yang, M.; Wang, Z.; Lin, X.; Qiu, Z.; Hirschfeld, D. R.; Gleason, S.; Mirzadegan, T.; Dunten, P. W.; Harris, S. F.; Villaseñ, A. G.; Hang, J. Q.; Heilek, G. M.; Klumpp, K. Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Benzyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett, 2010, 20, 4215-4218.
86. (b) Tang, G.; Kertesz, D. J.; Yang, M.; Lin, X.; Wang, Z.; Li, W.; Qiu, Z.; Chen, J.; Mei, J.; Chen, L.; Mirzadegan, T.; Harris, S. F.; Villaseñ, A. G.; Fretland, J.; Fitch, W. L.; Hang, J. Q.; Heilek, G.; Klumpp, K. Exploration of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. Bioorg. Med. Chem. Lett. 2010, 20, 6020-6023.
87. Kennedy-Smith, J. J.; Arora, N.; Roland Billedeau, J.; Fretland, J.; Hang, J. Q.; Heilek, G. M.; Harris, S. F.; Hirschfeld, D.; Javanbakht, H.; Li, Y.; Liang, W.; Roetz, R.; Smith, M.; Su, G.; Suh, J. M.; Villasenor, A. G.; Wu, J.; Yasuda, D.; Klumpp, K.; Sweeney, Z. K. Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase. Med. Chem. Commun., 2010, 1, 79-83.